

**Remarks**

Claims 7, and 9-11 are pending in this application.

Claims 1-6, 8 and 12-40 have been canceled without prejudice.


Claims 9 and 11 have been amended to change their dependency in view of cancellation of claim 8. No new matter is added.

Claims 7 and 9-11 stand rejected as allegedly being anticipated by Boschelli *et al.* This rejection is traversed. The Office Action indicates that the applied reference indicated that the compounds disclosed there in "could be efficacious for the treatment of various diseases". This is nothing more than an invitation to experiment. The physiological arts are unpredictable. There is nothing in the reference that would have given one of ordinary skill in the art a reasonable expectation that the compounds set forth in the present claims would in fact be useful in the treatment of myocardial infarction. Accordingly, withdrawal of the rejection is warranted.

In view of the foregoing, early allowance the present claims and passage of the application to issue is solicited.

Respectfully submitted,

Dated: December 17, 2008

By   
Talivaldis Cepuritis (Reg. No. 20,818)

OLSON & CEPURITIS, LTD.  
20 North Wacker Drive  
36th Floor  
Chicago, Illinois 60606  
(312) 580-1180